Creating awareness for improving performance and a new CFO
An Israeli pharmaceutical company trading on TASE engaged LHA upon completion of its U.S. IPO. The company was little known in the U.S. pre-IPO outside of a domestic commercial partnership. The analysts at the company’s syndicate firms a mix of biotechnology and medical devices as the pharmaceutical product was licensed to a firm covered by device analysts. The European Phase 3 study of an inhaled version of its flagship product was viewed as a binary event despite a robust pipeline and other commercial products.
- Developed and implemented comprehensive IR program with CEO, CFO and CSO involvement.
- With limited management time in the U.S., focused outreach on arranging multiple conference calls.
- Targeted primarily biotechnology investors, given the science and clinical/regulatory pathway.
- Maintained news flow that highlighted advances with other pipeline products.
Within the first six months of implementing the program, the company achieved significant results. The post-IPO momentum continued with 65 investor meetings, 10 investor conference calls, two earnings conference calls and presentations at six investor conferences. The company also garnered research coverage from a non-underwriter biotechnology analyst.